Medicinal Tablets — BharatSeal Smart DPR (May 2026)

Why this market is hot in 2026

The Indian pharmaceutical market is projected to reach US$130 billion by 2030, growing at a CAGR of 10-12%. India is the largest provider of generic drugs globally, accounting for 20% of global supply by volume. Government initiatives like Jan Aushadhi Yojana are boosting demand for affordable generic medicines. — IBEF Pharma Industry Report, May 2026

Small-scale contract manufacturing for niche generic formulations and OTC products is a growing segment, driven by new D2C health brands and smaller regional players who prefer outsourcing production rather than setting up their own facilities. This offers a viable entry point for micro-units with robust GMP compliance. — BharatSeal industry survey, May 2026

Product description

Tier-2/3 city industrial area, 1000 sqft dedicated clean room, 3-phase power, effluent treatment. The unit produces 2,00,000 blister pack (10 tablets) per year at full nameplate capacity, with a 5-year ramp from 30% to 80% utilisation. Sold at an average ₹15 per blister pack (10 tablets) blended across SKUs and channels. Target buyers span Retail pharmacies (e.g., Apollo Pharmacy, local chemists), Small hospitals, clinics, and primary health centers, Government procurement (e.g., Jan Aushadhi Kendras, State Health Departments), with online distribution via IndiaMART (B2B for bulk orders, contract manufacturing leads), TradeIndia (B2B for raw material sourcing and product listing), Government e-Marketplace (GeM) for public procurement tenders.

Industrial scenario (2026)

The Indian pharmaceutical market is projected to reach US$130 billion by 2030, growing at a CAGR of 10-12%. India is the largest provider of generic drugs globally, accounting for 20% of global supply by volume. Government initiatives like Jan Aushadhi Yojana are boosting demand for affordable generic medicines. Small-scale contract manufacturing for niche generic formulations and OTC products is a growing segment, driven by new D2C health brands and smaller regional players who prefer outsourcing production rather than setting up their own facilities. This offers a viable entry point for micro-units with robust GMP compliance. BharatSeal's editorial layer (12 'Hot in 2026' + 10 'Starter-friendly' tags) places this project in the wider 2026 Indian MSME landscape. Macro tailwinds include current PMEGP margin-money (15% urban, 25% rural, 35% special-category) plus the relevant sector schemes flagged below.

Basis & presumption of report

This DPR is prepared on the basis of BharatSeal's live market_inputs snapshot dated 2026-05-15, with capex prices, raw-material rates, wages, fuel, electricity and rent values resolved from primary public sources cited in Section 19. Plant capacity is 2,00,000 blister pack (10 tablets)/year. Working capital cycle is 4 months. Bank loan is sized at 75% of project cost over 5 years at 9.75% p.a., with PMEGP margin money assumed at 15% and beneficiary contribution at 10%. Depreciation follows the asset-specific lives in Section 16. Income tax is provided at 25% on positive PBT. Sundry debtors and creditors are taken at 15-day equivalents of revenue and COGS respectively — Indian MSME finance norm. The 5-year utilisation ramp is editorial (BharatSeal industry benchmark) and is the largest single judgement in the model — three scenarios (Section 6) and a sensitivity grid (Section 7) stress-test it.

Manufacturing process

1. 1
   Inward goods receipt + quality screening

   Verify raw-material specifications against the BOM; record batch numbers in inventory register.

   ⏱ 30-60 min per inward
2. 2
   Preparation + pre-processing

   Cleaning, sorting, grading, or pre-treatment as per the sector's standard production sequence.

   ⏱ 1-3 hr per batch
3. 3
   Primary production / processing

   Core production using the plant + machinery listed in Section 12. Operator-hours sized for 4-person crew across skill levels.

   ⏱ Continuous
4. 4
   In-process quality check

   Mid-stage parameter checks against the QC protocol below; rejected items returned for rework or scrapped.

   ⏱ 10-20 min per QC cycle
5. 5
   Finishing, packing + labelling

   Pack to retail/wholesale unit, apply MRP and statutory labels (BIS / FSSAI / nutritional / batch / expiry as applicable).

   ⏱ 30-60 min per finished batch
6. 6
   Outward dispatch + invoice

   GST-compliant invoice; e-Way Bill for shipments > ₹50k inter-state; logistics tie-up with local 3PL.

   ⏱ 15-30 min per dispatch

Inspection & quality control

Location advantages

• Sector cluster proximity

  API: IOL Chemicals and Pharmaceuticals Ltd., Granules India Ltd., local API distributors

• Buyer concentration

  Retail pharmacies (e.g., Apollo Pharmacy, local chemists) demand is concentrated in your operating region — see local-signal section for district-level checks.

• Scheme + subsidy access

  PMEGP + CGTMSE are actively releasing funds in 2026 — your nodal officer is the entry point.

• Skilled labour availability

  D.Pharm / B.Pharm degree (mandatory for Production Chemist/Proprietor for Drug License) runs in most Tier-2 cities, ensuring trained operators are reachable.

• Logistics + compliance ecosystem

  BIS-accredited labs + GeM vendor onboarding + APEDA / Spice Board / MNRE empanelment all available within 200 km in most operating states.

Are you eligible? (check before applying)

Every line below is a hard gate. If even one is "no", fix it before filing the PMEGP application — rejection at this stage costs you 30-60 days.

• Aged 18 or above on the date of PMEGP application.

  PMEGP scheme guidelines, Ministry of MSME
• Minimum education: Class VIII pass for project cost > ₹10 lakh (manufacturing).

  PMEGP-specific · PMEGP scheme guidelines, Ministry of MSME
• No prior PMEGP / PMRY / REGP grant claimed by you or your family.

  PMEGP-specific · PMEGP scheme guidelines, Ministry of MSME
• Project cost is within the PMEGP cap: ₹50 lakh for manufacturing. Medicinal tablets are categorised as 'manufacturing'.

  PMEGP-specific · PMEGP scheme guidelines
• Indian citizen with PAN + Aadhaar + active bank account.

  General MSME / Udyam registration
• Proprietor or designated Production Chemist must hold a valid B.Pharm or M.Pharm degree.

  State Drug Control Authority (SDCA) requirement
• Site has clear title (owned, leased ≥10 yrs, or family / panchayat allotted with NOC) and is located in a designated industrial zone suitable for pharma manufacturing.

  Bank underwriting + SDCA siting norm
• No active CIBIL default; minimum CIBIL score 650+ helps but isn't mandatory for PMEGP.

  Indian Banks Association underwriting norm

The numbers are one tap away

You've seen whether this business fits. The full Smart DPR — every cost, the 5-year P&L, EMI schedule, sensitivity, bank-grade accounting and the downloadable PDF — is free. Just sign in with your phone (30 seconds, no payment).

• Project cost (May 2026 prices)
• Means of finance & bank loan EMI schedule
• Steady-state profit & loss
• 5-year ramp projection & scenarios
• Sensitivity analysis
• Personal-fit & local-market checks
• Application sequence & timeline
• Subsidy stack, compliance & sourcing
• Bank-grade accounting (balance sheet, cash flow, depreciation)
• Full source citations